We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+31.06%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.34B
AUM Growth
+$386M
Cap. Flow
+$185M
Cap. Flow %
13.81%
Top 10 Hldgs %
66.32%
Holding
61
New
9
Increased
9
Reduced
28
Closed
9

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$48.6M
2
SAGE
Sage Therapeutics
SAGE
+$40.7M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$24.8M
4
TSRO
TESARO, Inc.
TSRO
+$22.5M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$19.1M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$25.1M
2
KA
Kineta, Inc. Common Stock
KA
+$19.2M
3
ANAB icon
AnaptysBio
ANAB
+$16.6M
4
BLUE
bluebird bio
BLUE
+$14.2M
5
WVE icon
Wave Life Sciences
WVE
+$7.09M

Sector Composition

Rank Sector Weight
1 Healthcare 83.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
1
Nektar Therapeutics
NKTR
$2.39B
$272M 20.3%
170,880
+37,700
+28% +$48.6M
NKTR icon
2
CALL
Nektar Therapeutics
NKTR
$2.39B
$163M 12.13%
102,060
+52,060
+104% +$67.1M
ANAB icon
3
AnaptysBio
ANAB
$1.58B
$115M 8.57%
1,104,022
-147,463
-12% -$16.6M
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
$90.4M 6.74%
4,088,229
+319,472
+8% +$6.28M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$58.9M 4.39%
1,918,350
+686,828
+56% +$19.1M
IFRX icon
6
InflaRx
IFRX
$250M
$40.3M 3.01%
1,399,030
-39,177
-3% -$1.03M
BPMC
7
DELISTED
Blueprint Medicines
BPMC
$39.6M 2.95%
432,063
-17,937
-4% -$1.55M
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$38.6M 2.88%
+239,619
New +$40.7M
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$37.4M 2.79%
767,363
-32,637
-4% -$1.7M
DRNA
10
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$34.4M 2.57%
3,600,954
-55,715
-2% -$601K
TBPH icon
11
Theravance Biopharma
TBPH
$874M
$31.5M 2.35%
1,300,000
+400,000
+44% +$11M
RCKT icon
12
Rocket Pharmaceuticals
RCKT
$340M
$28.5M 2.12%
+1,519,891
New +$24.8M
GTHX
13
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$26.7M 1.99%
719,985
-177,520
-20% -$4.74M
ASND icon
14
Ascendis Pharma A/S
ASND
$16B
$24.3M 1.81%
371,739
+71,739
+24% +$4.03M
AVXS
15
DELISTED
AveXis, Inc. Common Stock
AVXS
$23.7M 1.77%
192,094
-7,906
-4% -$940K
ARGX icon
16
argenx
ARGX
$53.4B
$22.4M 1.67%
278,536
-11,464
-4% -$866K
QTNT
17
DELISTED
Quotient Limited Ordinary Shares
QTNT
$20.2M 1.51%
107,271
-4,932
-4% -$889K
CLSD
18
DELISTED
Clearside Biomedical
CLSD
$20.2M 1.5%
125,392
-4,000
-3% -$487K
TSRO
19
DELISTED
TESARO, Inc.
TSRO
$20M 1.49%
+350,000
New +$22.5M
VNDA icon
20
Vanda Pharmaceuticals
VNDA
$307M
$16.1M 1.2%
+957,821
New +$16M
NBIX icon
21
Neurocrine Biosciences
NBIX
$16.8B
$15.8M 1.18%
191,112
-8,888
-4% -$751K
OMER icon
22
Omeros
OMER
$857M
$14.7M 1.09%
1,314,118
+439,118
+50% +$6.17M
QTRX icon
23
Quanterix
QTRX
$164M
$14.4M 1.08%
847,789
– –
ANAB icon
24
CALL
AnaptysBio
ANAB
$1.58B
$13.5M 1%
129,400
-5,600
-4% -$631K
YARW
25
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$12.7M 0.94%
+94
New +$11.4M
1
2 3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q1 2018 Portfolio in Review

As of Q1 2018, Cormorant Asset Management held 61 positions worth $1.34B, up 40% from $955M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Cormorant Asset Management deployed $185M of net new capital in Q1 2018, opening 9 new positions and adding to 9 existing holdings. Its largest new stake was Sage Therapeutics: 239,619 shares worth $38.6M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was AnaptysBio, an estimated $16.6M trimmed.

  • Cormorant Asset Management's largest Q1 2018 buy was Sage Therapeutics: 239,619 shares worth $38.6M.
  • Cormorant Asset Management added most to Nektar Therapeutics in Q1 2018, an estimated $48.6M increase.
  • Cormorant Asset Management's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $16.6M.
  • Cormorant Asset Management fully exited Juno Therapeutics, Inc. in Q1 2018, selling an estimated $25.1M.
  • Cormorant Asset Management's ten largest holdings make up 66% of its $1.34B portfolio in Q1 2018.
  • Cormorant Asset Management opened 9 new positions and closed 9 in Q1 2018.
  • Cormorant Asset Management's portfolio value rose 40% quarter-over-quarter to $1.34B.

Based on Cormorant Asset Management's 13F filing for Q1 2018, filed 15 May 2018.